Navigation Links
XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
Date:11/17/2011

FRANKFURT, Germany, Nov. 17, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that results from five studies examining XEOMIN® (incobotulinumtoxinA), a botulinum neurotoxin type A preparation free from accessory proteins, will be presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Orlando, Fla.

The first poster being presented at the meeting, titled "Sustained efficacy of incobotulinumtoxinA (XEOMIN®; botulinum neurotoxin type A free from accessory proteins) in cervical dystonia demonstrated by investigator and patient-rated outcomes," assessed the long-term efficacy and tolerability of XEOMIN® in cervical dystonia in a setting similar to clinical practice. The prospective, multicenter, open-label single-arm Phase IV study found that XEOMIN® showed sustained efficacy and was well tolerated in the treatment of cervical dystonia for up to 121 weeks. [Poster 130; Dressler, et al.]

The second poster, titled "Significant and sustained efficacy of incobotulinumtoxinA (XEOMIN®; botulinum neurotoxin type A, free from accessory proteins) in upper limb spasticity," included two studies. The first consisted of a randomized, double-blind, placebo-controlled main period and an open-label extension period and evaluated patients with upper limb (UL) post-stroke spasticity. The second was a randomized study of two dilutions of incobotulinumtoxinA that assessed patients with UL spasticity of various etiologies. Study results showed that incobotulinumtoxinA was well tolerated and demonstrated significant, sustained efficacy in UL spasticity. [Poster 138; Kanovsky, et al.]

"The positive findings presented at AAPM&R reinforce that XEOMIN® is a safe and effective option for patients in need of treatment for certain movement disorders," said Petr Kanovsky, MD, PhD, Department of Neurology, Palacky University Medical School, Olomouc, Czech Republic, a
'/>"/>

SOURCE Merz Pharmaceuticals GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
2. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
3. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
6. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
7. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
8. New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI
9. Abbott Statement on the Results of the AIM-HIGH Study Presented at AHA 2011
10. Positive Results from Phase 2 Trial of Mesoblasts Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
11. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  A new analysis of Centers for Medicare and ... shows that 81 percent of seniors chose lower-cost preferred ... at certain pharmacies. The findings were released by ... now the foundation of Medicare Part D," said Pharmaceutical ...
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... Nov. 12 Zimmer Holdings, Inc. (NYSE: ZMH ; ... $1.0 billion of its senior unsecured notes in an underwritten ... 2019 and $500.0 million of 5.75% notes due 2039. The ... their Treasury benchmark, and the 30-year notes were priced at ...
... new treatment for autism appears to normalize brain function, ... BCIA-EEG. , In addition to high serotonin ... pattern reflecting impaired brain function, particularly in areas of ... bonding. , However, Quantitative EEG,s conducted ...
Cached Medicine Technology:Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, ... Health Alliance (PPHA). The PPHA's passion for others' well-being ... NFL greats, treated for obstructive sleep apnea (OSA) has propelled ... cause in the valley. The most recent plans for an ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Projects Significant Expansion of Drug-Treated Population, But Only For ... New ... from Decision Resources, WALTHAM, Mass., Sept. 5 Decision Resources, ... and,healthcare issues, has found that a significant proportion of hepatitis C,virus ...
... Technology Services, or,CTS, (http://www.ctsmius.com ) announced that ... the most stringent medical devices by,the Food and ... company,is continuing to focus on its growth in ... the company from well-known automotive supplier,MSX International, last ...
... Than 35 Doctors Grow as MedHelp Focuses on Answering More ... Consumer ... the leading online,health community connecting people to medical experts, information ... L. Johnson, M.D. and Stephen Ryu, M.D. have joined their,premier ...
... Award-Winning ... Technology of AnyTrack GPS-100 Model, IRVINE, Calif., Sept. ... of GPS tracking products and services,announced two enhanced GPS ... the GPS-100. The new AnyTrack GPS-130 is a ...
... Symbol: AKL, MONTREAL, Sept. 5 /PRNewswire-FirstCall/ ... development company focused on developing therapies for ... positive results from the,double-blind extension part of ... demonstrated statistically significant differences compared to,placebo in ...
... 2007) Today, the Canadian Institutes of Health Research ... to the results of research it has funded. CIHR ... research articles are freely available online within six months ... to research findings is a defining feature of science, ...
Cached Medicine News:Health News:Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options 2Health News:Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications 2Health News:MedHelp to Add Top Stanford Surgeons and Specialized Forums to Online Health Community 2Health News:MedHelp to Add Top Stanford Surgeons and Specialized Forums to Online Health Community 3Health News:New AnyTrack GPS Devices Track Assets Indoors, Outdoors or Hidden 2Health News:New AnyTrack GPS Devices Track Assets Indoors, Outdoors or Hidden 3Health News:AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial 2Health News:AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial 3Health News:Open access to health research publications 2
VasoSeal ES is a extravascular arterial sealing. It utilizes a unique temporary arterial locator system which provides an easier and surer method of locating the femoral artery....
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
... Ultra thin collagen coated highly ... ultra thin wall construction offers ... The Hemacarotid UltraThin Patch provides ... conformability, and healing, without suture ...
Medicine Products: